The iPhone maker's shares [rallied for a second day]( ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss ...

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Lilly’s stock tumbled as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...